Compare BioNano Genomics Inc (BNGO) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Prologis Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Prologis Inc trades at $140.73 (market cap $132.57B). The key difference: Prologis Inc is far larger — about 9705× BioNano Genomics Inc's market cap, and Prologis Inc pays a 3.07% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | PLD | |
|---|---|---|
Market Cap | $13.66M | $132.57B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $149.96 |
52-Week Low | $1.06 | $104.81 |
Enterprise Value | $16.26M | $167.31B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Prologis (PLD) trades at $140.46, up 1.25% on the day, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, and the company announced a major $18.8 billion acquisition of Segro (WSJ, 2026-08-04). Valuation ratios are elevated, with a P/E of 31.07 and P/S of 14.54, while profitability remains robust with a net income margin of 45.79%.
The outlook is mixed: analyst consensus is bullish with a $159.22 price target, but the Segro acquisition introduces integration risks and leverage concerns. Upside hinges on successful merger execution and sustained industrial real estate demand, while downside risks include debt load and economic slowdowns impacting logistics property valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
